View More Recent Stories
-
Esperion Therapeutics (ESPR) Announces New Drug Submissions in Canada for NEXLETOL and NEXLIZET Treatments to Reduce LDL-C and Cardiovascular Risk
-
Esperion Therapeutics (ESPR): Otsuka Submits New Drug Application in Japan for Bempedoic Acid in the Treatment of Hypercholesterolemia
-
H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
-
Esperion Therapeutics (ESPR) EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
-
Esperion (ESPR) Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL and NEXLIZET
-
Esperion Therapeutics (ESPR) Misses Q2 EPS by 17c, provides guidance
-
H.C. Wainwright Reiterates Buy Rating on Esperion Therapeutics (ESPR)
-
Esperion Therapeutics (ESPR) Announces Monetization of European Royalties and Concurrent Payoff and Termination of Existing Revenue Interest Facility
-
BofA Securities Downgrades Esperion Therapeutics (ESPR) to Underperform
